MTOR and renal cell carcinoma: In addition, Kaplan–Meier survival analysis of RCC patients received targeted therapies (mTOR inhibitors or tyrosine kinase inhibitor, Supplementary Table 1) from TCGA showed that PDPK1 was negatively associated with patient survival after treatments (P=0.043, HR=2.558, Figure 5).